BridgeMD
New treatment option for Gastrointestinal Stromal Tumors
Official title Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
ClinicalTrials.gov ID: NCT07618377
What this study is testing
What is DCC-2618?
DCC-2618 is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for gastrointestinal stromal tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants with a histologically confirmed diagnosis of GIST.
- Participants who are refractory or intolerant to treatment with at least imatinib, sunitinib, and regorafenib.
- Participants with at least one measurable lesion per the modified Response Evaluation Criteria in Solid Tumors (mRECIST) within 28 days prior to the...
- Participants with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
You likely can't join if
- Participants with a concomitant or prior history of severe hypersensitivity reactions to other tyrosine kinase inhibitors.
- Participants with uncontrolled diabetes mellitus.
- Participants with a systemic infection requiring treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Kashiwa, Chiba, Japan
- Tokyo, Chuo-ku, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kashiwa, Chiba, Japan; Tokyo, Chuo-ku, Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.